Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Adopts Shareholder Rights Plan

NEW YORK, June 20 - Luminex said Wednesday its board of directors has adopted a shareholders rights plan designed to prevent hostile takeover bids.

Luminex, an Austin, Texas-based developer of microarray bead technology, said that the decision to adopt the rights plan was not a reaction to any outside attempt to takeover the company.

"The adoption of the rights plan is merely a means of safeguarding against abusive takeover tactics and is not in response to any accumulation of shares or hostile takeover attempt,” Mark Chandler, Luminex’s CEO said in a statement.

“In fact, we are not aware of any effort to acquire the company,” Chandler said.

The rights plan has a 20 percent trigger, meaning that it will only go into effect if an outside party accumulates 20 percent or more of the company’s stock.

Recently, several companies, including Informax, Orchid BioSciences, Aclara,  Large Scale Biology, and Illumina,  have all adopted such plans.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.